---

Procedure

Excision (or subtotal mastectomy) Total mastectomy Nipple sparing mastectomy Modified radical mastectomy Radical mastectomy Other Not specified

---

Specimen Laterality

Right Left Not specified

---

Tumor Size

Microinvasion only (≤1 mm) Size > 1 mm No residual invasive carcinoma Size of largest invasive focus cannot be determined

---

Histologic Type

Invasive ductal carcinoma of no special type Micro-invasive carcinoma Invasive lobular carcinoma Invasive carcinoma with lobular features Invasive carcinoma with ductal and lobular features (“mixed type carcinoma”) Mucinous carcinoma Tubular carcinoma Invasive cribriform carcinoma Invasive micropapillary carcinoma Solid papillary carcinoma with invasion Apocrine adenocarcinoma Metaplastic carcinoma Encapsulated papillary carcinoma with invasion Intraductal papillary adenocarcinoma with invasion Adenoid cystic carcinoma Neuroendocrine tumor Neuroendocrine carcinoma Invasive carcinoma, type cannot be determined No residual invasive carcinoma Other histologic type

---

Histologic Grade

---

Overall Grade is automatically calculated based on the Nottingham selections above

---

+ Tumor Focality

Single focus of invasive carcinoma Multiple foci of invasive carcinoma Cannot be determined

---

Ductal Carcinoma In Situ About extensive intraductal carcinoma

×

A note about extensive intraductal carcinoma

No DCIS in specimen DCIS is present in specimen DCIS is present in specimen, without extensive intraductal component DCIS is present in specimen, with extensive intraductal component Only DCIS is present after presurgical (neoadjuvant) therapy

---

+ LCIS in specimen

No LCIS in specimen Present

---

Tumor Extension

No skin, nipple or skeletal muscle involvement Invasive carcinoma directly invades into the dermis or epidermis without skin ulceration Invasive carcinoma directly invades into the dermis or epidermis with skin ulceration Satellite skin foci of invasive carcinoma are present DCIS involves nipple epidermis Carcinoma invades skeletal muscle Carcinoma invades into skeletal muscle and into the chest wall Not applicable

---

Margins - Invasive carcinoma

Cannot be assessed Uninvolved by invasive carcinoma Involved by invasive carcinoma

---

Margins - DCIS

Cannot be assessed Uninvolved by in-situ carcinoma Involved by in-situ carcinoma

---

Regional Lymph nodes

Check here if any lymph nodes submitted?

---

Treatment Effect

No known presurgical therapy No definite response to presurgical therapy in the invasive carcinoma Probable or definite response to presurgical therapy in the invasive carcinoma No residual invasive carcinoma is present in the breast after presurgical therapy

---

+ Lymphovascular Invasion

Not identified Present Cannot be determined

---

Pathologic Staging (pTNM)

TNM Descriptors (select all that apply)

Not applicable m r y

pT

pT0: No evidence of primary tumor pTis (DCIS): Ductal carcinoma in situ pTis (Paget): Paget disease of the nipple not associated with invasive carcinoma and/or DCIS in the underlying breast parenchyma pT1mi: Tumor ≤1 mm in greatest dimension pT1a: Tumor >1 mm but ≤5 mm in greatest dimension pT1b: Tumor >5 mm but ≤10 mm in greatest dimension pT1c: Tumor >10 mm but ≤20 mm in greatest dimension pT2: Tumor >20 mm but ≤50 mm in greatest dimension pT3: Tumor >50 mm in greatest dimension pT4a: Extension (invasion) to the chest wall pT4b: Ulceration and/or ipsilateral macroscopic satellite nodules and/or edema (including peau d’orange) of the skin (not inflammatory carcinoma) pT4c: Both T4a and T4b are present pT4d: Inflammatory carcinoma

pN

pNX: Regional lymph nodes cannot be assessed pN0: No regional lymph node metastasis identified pN0 (i+): ITCs only (malignant cell clusters no larger than 0.2 mm) in regional lymph node(s) pN0 (mol+): Positive molecular findings (RT-PCR), but no ITCs detected pN1mi: Micrometastases (larger than 0.2 mm, but none larger than 2.0 mm) pN1a: Metastases in 1 to 3 axillary lymph nodes, at least 1 metastasis larger than 2.0 mm pN1b: Metastases in ipsilateral internal mammary sentinel nodes, excluding ITCs pN1c: pN1a and pN1b combined pN2a: Metastases in 4 to 9 axillary lymph nodes (at least 1 tumor deposit larger than 2.0 mm) pN2b: Metastases in clinically detected internal mammary lymph nodes with or without microscopic confirmation; with pathologically negative axillary nodes pN3a: Metastases in 10 or more axillary lymph nodes (at least 1 tumor deposit larger than 2.0 mm) pN3a: Metastases to the infraclavicular (Level III axillary lymph) nodes pN3b: pN1a or pN2a in the presence of cN2b pN3b: pN2a in the presence of pN1b pN3c: Metastases in ipsilateral supraclavicular lymph nodes

pM

pMx: Not applicable pM1: Histologically proven metastases larger than 0.2 mm

---

- ANCILLARY HORMONE RECEPTOR STUDIES -

---

- BIOMARKER METHODOLOGY -